Imescia is developing a new polymer prodrug technology that promotes tumor accumulation of anti-cancer drugs and preferential release within the tumor microenvironment. This technology improves anticancer drug efficacy and decreases toxicity. Our lead program IMA-01 is the combination of our technology with mertansine, a highly promising anticancer drug. Our goal is to bring IMA-01 to proof of efficacy in clinical trials phase 2 by the end of 2026.
5 rue Jean Baptiste Clément 92290 Chatenay Malabry
Targeted indications : Breast cancer, Gastrointestinal cancers, Gynecological cancers